Collagen is the major component of the tumor microenvironment and participates in cancer
fibrosis. Collagen biosynthesis can be regulated by cancer cells through mutated genes …

In less than 10 years, melanoma treatment has been revolutionized with the approval of
tyrosine kinase inhibitors and immune checkpoint inhibitors, which have been shown to …

BRAF inhibitor therapy may provide profound initial tumor regression in metastatic
melanoma with BRAF V600 mutations, but treatment resistance often leads to disease …

Malignant melanoma is a neoplasm originating in the melanocytes in the skin. Although
malignant melanoma is the third most common cutaneous cancer, it is recognized as the …

Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …

Simple Summary The response to pharmacological treatments is deeply influenced by the
tight interactions between the tumor cells and the microenvironment. In this review we …

Cancer is one of the major causes of death worldwide. Its treatments usually fail when the
tumor has become malignant and metastasized. Metastasis is a key source of cancer …

The BRAFV600E mutation is associated with melanoma development and its detection in
circulating-free DNA cannot be observed in all melanoma patients harboring this mutation in …

Melanoma is recognized as the most dangerous type of skin cancer, with high mortality and
resistance to currently used treatments. To overcome the limitations of the available …

BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is
initially highly effective, but almost all patients relapse within a few months. Understanding …